Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention.
about
Use of Thrombopoietin Receptor Agonists in Childhood Immune ThrombocytopeniaImmune thrombocytopeniaThe Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and PathogenesisCyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy.Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions.Treatment of immune thrombocytopenic purpura: focus on eltrombopag.Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions.Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists.Eltrombopag in patients with chronic liver disease.Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy.Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias.Eltrombopag-based combination treatment for immune thrombocytopenia
P2860
Q26795730-FB92E22B-F012-4B6C-8050-6186B3D826F6Q26830918-F2504D9A-6EED-40FE-B7D5-4E12B64AE16BQ28068881-62366E89-5646-4183-91AC-4EEC09129129Q33340291-8E010C48-F235-4413-AF7E-19C5C423A245Q33344528-FCB5ED26-35C4-49EE-B06F-97299D39083AQ33385976-9DA065FE-8A1F-40D7-BA09-9C32ED19499CQ33396650-B259408B-F67A-4F72-A137-5A4B8B6D065DQ33400018-47E75A16-C10C-4B60-96AE-4F15A837BBDDQ33402387-30C3AEC1-8923-4738-A44C-8FCBD031A08DQ33402611-95872C11-51F2-40BB-8005-B11F149A805DQ33402843-7209140F-EAB5-47F4-8A00-DFFCDABF79D3Q33406181-26FDD460-56CF-4B0C-A079-7E8F57091169Q33429738-B121900C-A320-4BC7-B666-10D08DA1FA0AQ33442686-BC6C0C10-8932-4DD3-A07B-21687BEE5BB2Q57818187-FD78EFDD-CADB-4E62-BE52-C6CF2F784A1C
P2860
Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@ast
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@en
Endogenous TPO
@nl
type
label
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@ast
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@en
Endogenous TPO
@nl
prefLabel
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@ast
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@en
Endogenous TPO
@nl
P356
P1433
P1476
Endogenous TPO (eTPO) levels i ...... for therapeutic intervention.
@en
P2093
P2860
P304
P356
10.1002/STEM.5530160719
P478
16 Suppl 2
P577
1998-01-01T00:00:00Z